Jocelyn Marquis has over 15 years of experience in the pharmaceutical and medical industries. She has held scientific and strategic roles at companies such as Medzone, Xprtiz, AstraZeneca, Biovail Pharmaceuticals, XpO, and Actelion Pharmaceuticals. Her experience includes providing scientific and strategic consultation, project management, marketing, training, and continuing medical education. She has strong skills in building relationships, communicating scientific information, and identifying new business opportunities.

1. Jocelyn Marquis M.Sc
7095 Avenue de la Source
Anjou-sur-le Lac
Anjou
Cellular : 514-295-6767
jocelyn.marquis@sympatico.ca
Profile:
Highly scientific individual, capable of translating evidences into
meaningful people benefit
Result oriented, successful individual with proven track record in
niche markets
Highly motivated individual always looking to further advance and
enhance both knowledge and relationships
Strong personal skills in building relationship with KOL both at
national and international level
Entrepreneurial and innovative approaches toward objectives
Autonomous individual with significant adaptability
Strong asset in training, CME and marketing
A unusual ability to find information, to analyze, share and maximize
it
Professional Experience:
Medzone
Strategic and Scientific Consultant
November 2009 to date
Company / Situational Background:
Medzone , as an independent consultancy, is involved in meeting
planning and project management of pharmaceutical and medical fields.
In best answering customers needs, Medzone has developed novel
strategies in CME in order to enhance engagement and opportunities.
Achievements:
Acted as a scientific advisor for the delivery of complex medical
information and communication projects
Contributed valuable strategic input for the expansion of current
business activities and revenue
Provided creative ideas to attract new business opportunities and to
develop relationships with potential clients
Created avenues for the increasing the company's network of
professional contacts and business partners
Maintained direct contact and ongoing accessibility to the business
owner for the purpose of ongoing feedback and regular consultations
Xprtiz
Director, Strategic and Scientific Affairs
January 2008 to date
Company/ Situational Background:
Xprtiz specializes in providing insights on current and future trends
in pharmaceutical niche markets. With a perspective ranging from design
to launch, in marketing, medical, CME and training, Xprtiz provide
coherence, scientific correctness and technical integration and know-

2. how.Pro-active,transforming inertia into innovation, knowledge in
action, Xprtiz has the practiced ability to bring together
business,science, technology and the human element factor into the
equation, breathing life into any project and or initiative in search
of an optimal solution.
Actual /Completed Project :
Strategic Consultation on a palliative care agent in Oncology: from
redaction of product monograph to 5 year planning : Building a brand. A
pitch with Enzyme
Astra Zeneca
Contract position Maternity Leave replacement
Neuroscience Medical Liaison
July 2009 to April 2010
Company/ Situational Background:
Astra Zeneca is a key player in the pharmaceutical field within a
significant and extensive pipeline ranging from oncology,
cardiovascular and CNS among others. In preparing for novel molecules,
AZ has build one of the most solid medical liaison team to further
enhance its visibility and presence within thought leaders of the
various therapeutic filed it is a leader.
Achievements:
Rapidly established as a scientific resource internally and externally
Attendee and analyst for many courses / symposium
Massachusett General Hospital / Harvard Psychopharmacology
Stal Quebec Psychopharmacology preceptorship
Canadian Psychiatry Association
Scientific literature review for CNS MSL and field representatives
Site review for potential clinical trials
In collaboration with Medical Advisor
Project consultant for training programs for doctors
Reviewer for scientific content
Expansion into rheumatology and pain market as well
Premarketing and prelaunch activities
Symposium of Clinical efficiency in Psychiatric trials
A one day program ( 2010 ) in sharing best practices in achieving
maximal enrollment
Co-Morbidities Symposium
As a prelaunch activity towards newer indications, this symposium
targets parallel symptoms as potential for out of indication usage of
medication to support future expansion beyond actual indications
Biovail Pharmaceuticals
Contract position
Neuroscience Specialist and Key Account Manager
April 2009 to July 2009
Company/ Situational Background:
Biovail, through the acquisition of Preswick Pharmaceuticals, has
branched into brand name drugs with Nitoman, a drug indicated for the
movement disorders. Psychiatrists and Neurologists are involved in
treating this pathology, that is related in the majority of cases to
neuroleptic therapy. A challenge for this market is identification of
these patients, mostly depressive and schizophrenic.The business unit
was dismantled in December 2009
Achievements:

3. Rapidly established as a key scientific resource both internally and
externally
Attendee and analyst for many courses / symposium
APA 2009
AMPQ 2009
Competitive intelligence and new literature analysis
APA 2009
Project Leader for many CME
Consulting role in training and building Key Account tools
Provincial scientific and field resource for Nitoman within
Neuroscience and CNS sale forces
XpO
Scientific and Strategic Advisor
January 2005 to April 2009
Company/ Situational Background:
XpO is an integrated healthcare communication firm involved in brand
( marketing and educational material), logistical themes, and
conference ( event as well conference) development. XpO offers service
ranging from marketing to booth exhibit design and management, as well.
Among their many customers, WebMD is one of the best known as well as
theheart.org, but it also has many highly niched biotechnological
companies as well, in various therapeutic fields such as cardiology,
hepatitis, HIV and PAH among many. From January 2005 to December 2008,
these functions were on a part time basis and attendance to conferences
were also an asset in my role as Scientific Advisor for CCPE, which
could not pay for me attending these conferences.
Achievements:
Scientific and Logistic consultant for many vendors in various
therapeutic fields
Oncology, HIV and Cardiology
Project Leader on many advisory boards
HIV and Cardiology
Attendee and analyst for many courses / symposium
ASCO, AHA, APA, ACR, ISHLD,ACCME and others
Project manager for for WebMD / Medscape symposium and WebMD clients
Boston Scientific at HFSA
Novartis at AHA
Actelion at PAH venues in Canada
CME / CHE logistical planner for the above mentioned symposia
Business plan and strategic planning of opportunities
Web and logistical development
Council for Continuing Pharmaceutical Education
Scientific Advisor
November 2005 to December 2008 as in House Advisor
Company/ Situational Background:
The Council for Continuing Pharmaceutical Educational, a non-profit
organization, is responsible for accreditation of healthcare
representatives as well as providing them with continuing education in
both therapeutic knowledge as well as newer field such as
pharmaceutical management. In providing such services to the
pharmaceutical community, the CCPE must keep track on all of the newer
advances in our industry, and new insights on diseases. I had to be

4. fluent in 24 various therapeutics field ranging from Cardiology,
Infectious diseases, to Oncology among others.
Achievements:
Scientific and strategic recommendations based on competitive
intelligence
Consultant for various member companies on new business opportunities
and launches
Speaker at various venues on behalf of CCPE (Univ de Laval
Pharmaceutical management MBA)
Scientific review of courses and new course material
Author and Subject matter expert on various subjects within new course
material (PAH in rheumatology, Evidence Based Medicine and Metabolic
Syndrome and Project leader for the New Oncology Course curriculum
Evidence Based Medicine Speaker and Workshop Consultant
Just in time / tailored made course construction from existing CCPE
material, writing of new material and reviewing third party material
Actelion Pharmaceuticals
January 2003 – July 2005
Associate Manager Marketing and Training
March 2004 – July 2005
Product :Tracleer in Pulmonary Arterial Hypertension
Company/ Situational Background:
Actelion is an independent biopharmaceutical company discovering,
developing and marketing drugs for high unmet medical needs. In doing
so, it brought a new light on pulmonary arterial disease, a rare
disease affecting 1 or 2 individuals per million, building it into a
billion dollars a year business. The challenge resided in making
physicians aware of this issue and integrating the involved physicians(
cardiology, pneumology and rheumatology) into a team. I first joint
them in a field based position and was promoted into marketing,
training and CME functions
Marketing Achievements:
Activities organized
Cardiology Workshop for field application, from conception to CME
deployment, with development of speakers / KOL
Endothelin Symposium at CCS 2004
Litterature analysis, program building and review
Speaker training
Prelaunch activities for newer indications
First Canadian Pediatric Congenital Cardiologists meeting at Hop Ste-
Justine
Prelaunch activities into cardiac indications ( Eisenmenger`s syndrome)
Zavesca Launch in Montréal Sept 2004
An entire Literature Review and Tool Objectives development for field
Interaction with Actelion International colleagues
Market intelligence (Stride 2, Martine Clozel)
Medical Science Liaison facilitator
Training Acheivements :
In House and field training of 5 new representatives from 2004 to 2005
and 2 MSL
Scleroderma training / patient discussion at Hôpital Notre-Dame with Dr
Jean-Luc Senécal Congenital Heart Disease Preceptorship for MSL and
Medical / Marketing team organized at Institut de Cardiologie de

5. Montréal as pre-launch activity
Complete literature review in form of an interactive CD for both field
representatives and MSL
Journal Review and marketing direction for key papers
Market intelligence & Market analysis of potential competition
Manager Scientific and Commercial Affairs (Pulmonary Arterial
Hypertension)
January 2003- March 2004
Territory covered: Quebec and the Maritimes provinces
Scientific field activities in light of absence of MSL
Facilitator and liaison for the initiation of PAH clinic in Halifax
CME Activities organized
Dr Olivier Sitbon multiple CME in the province of Quebec
In-house Halifax 2 days clinic preceptorship with Dr John Granton
Advisory Board meeting for HIV physicians
ICAAC with Dr Olivier Sitbon (Fall 2003)
Dr Lewis Rubin’s multiple CME for the province of Quebec (Jan 2004)
Dr Peter Docherty St-Johns PAH in house training
Agouron Pharma
Virology specialist
March 1998 –December 2002
Product : Viracept in HIV
Company/ Situational Background:
Now integrated within Pfizer, Agouron Pharmaceuticals, formed to
exploit the potential of rational drug design. It became a major
biotechnology company and its first rationally designed drug,
Viracept ,a leading HIV protease inhibitor at one point. It represented
in Montreal, half of all scripts for this class of agents through
innovative marketing and drug positioning based on a favorable
genotypic mutation making it a first line option that would preserve
future options.
Pre-launch activities prior to launch
Managing Extended access programs, scientific literature requests and
symposia
Involvement in building the launch program both nationally and
provincially
Provincial program from speakers to content
Field Medical / Science Liaison activities leading to many abstracts
and posters
ICAAC with Dr Jean-Guy Baril ( Clinique Méd Quartier Latin)
Diarrhea Dietary Management program initiator at Clinique Médicale du
Quartier Latin
Calcium and dietary intervention as a solution to moderate to severe
diarrhea in 60-80% of patients
Medical and Marketing intelligence activities
Literature search
Clinical trials field activities
CME programs, from initiation, to material review to training of

6. speakers
Building of the first training in genotypic resistance in Canada
Dr Rodger MacArthur (Wayne State University, Detroit) genotyping
preceptorships for Canadian HIV specialists
Pediatric HIV preceptorship program at Ste-Justine and Montreal
Children`s Hospital with Dr Patricia Garcia (Northwestern
University,Chicago)
Programme National de Mentorat sur le VIH-SIDA
This program targeted infectious diseases physicians in order to
increase their knowledge
First Clinic week-end for Clinique Médicale du Quartier Latin
As of the most significant HIV clinic in Montreal, we build a
complete scientific week-end program for the physicians as well as a
parallel program for nurses and administrative personnel
CPAVIH, and multiple patients group in the province
Agouron had bi-weekly CME presence and activities in the territory
Patient liaison with CPAVIH
In-house training of colleagues
Zeneca Pharma
July 1996 to March 1998
Oncology sales specialist
Products : Arimidex (breast cancer hormonal therapy), Tomudex
(colorectal cancer) and Merrem (antibiotic)
Company/ Situational Background:
Zeneca, a leading force in breast cancer with tamoxifen, was
introducing 2 new agents in oncology as well as a new carbapenem. In
doing so, they were looking for experience in antineoplastic agents and
hormonal therapy for breast cancer. I acted as a reviewer for
promotional material adapting them to our Canadian market.
Responsible for full listing of Arimidex despite initial restricted
provincial formulary listing obtained through Government Affairs
Tomudex Pre-launch and Marketing team member for Canada
Both at office and field level in Quebec
Marketing review
Pricing task force
Scientific and clinical trial review
ESCO Tomudex World Marketing Task Force Member
Arimidex trainer for field expansion summer 1997
Field and in-house training of new representatives
Field Consultant for Quebec colleagues
Bristol Myers Squibb
April 1990 to July 1996
Oncology and HIV sales representative
Key Products :Taxol , Vepesid, Ifosfamide (all antineoplastic agents),
Megace (Breast Cancer Hormonal
therapy), Videx (HIV) and Cefipime (antibiotic)
Company/ Situational Background:
Fresh out of university, I joined BMS Oncology to promote what was
the most significant oncology portfolio at that time, with significant

7. breakthrough, such as the first taxane, paclitaxel.
Representative of the year 1991
Field and in-house training of new representatives
Launches and pre-launch activities
Pre-launch activities for Taxol, Cefepime and Stavudine
Market introduction
Hospital and provincial formulary working group ( Régie du Medicament
( Québec ) )
Taxol anti-generic task force
John Hopkins Oncology preceptorship
Presence at ASCO every year